Two in three people using GLP-1 weight-loss medications conceal their treatment from friends or family, according to new research released by Simple Online Pharmacy on World Obesity Day. While more than half of patients say their social treatment improves after losing weight, the method behind their results—medical intervention—remains heavily scrutinized.
The study, described as the largest of its kind in the UK, analyzed responses from more than 3,000 GLP-1 patients alongside a separate survey of 2,000 consumers. Researchers found that secrecy is a defining feature of the GLP-1 experience, reflecting persistent stigma surrounding medical weight-loss treatments.
“People living with obesity are often told their weight is simply about willpower,” said Abdal Alvi, Chief Clinical Officer at Simple Online Pharmacy. “Yet when they seek medical support, they are criticised for ‘cheating’ or taking the ‘easy way out.’ People are judged both for having a chronic disease and for treating it. To help people live healthier lives, we need to recognise obesity as a medical condition and reduce the stigma surrounding treatment.”
According to the findings, 38% of patients reported being judged for using GLP-1 medications. Nearly 80% said they had been accused of taking the “easy way out,” and 68% reported being told to “eat less and move more.” For 21% of respondents, fear of social stigma directly influenced their decision to pursue treatment.
The pressure to conceal treatment is particularly pronounced among younger adults. Seventy-four percent of Gen Z patients reported hiding their use of GLP-1 drugs, compared with 60% of Baby Boomers and 43% of the Silent Generation. Women were also more likely than men to keep their treatment private, at 69% versus 53%.
Researchers noted a paradox: the groups most open to medical intervention and most likely to recognize obesity as a chronic condition are often the same groups who feel the greatest need to keep their treatment secret.
Despite public perceptions that GLP-1 medications offer a shortcut to weight loss, patient-reported outcomes suggest a more complex reality. Ninety-two percent of respondents said their overall health had improved, citing increased energy, better mobility and greater confidence. Additionally, 88% said the treatment helped them maintain healthier lifestyle habits.
On average, patients reported trying four other weight-loss strategies before starting GLP-1 medication, indicating that pharmaceutical treatment often follows years of unsuccessful efforts rather than replacing lifestyle changes.
The study highlights a significant gap between public perception and clinical evidence. While GLP-1 therapies have demonstrated effectiveness and meaningful health benefits, stigma and outdated narratives about obesity may be limiting broader acceptance and uptake. Researchers say aligning public understanding with medical evidence will be key to improving access, adherence and long-term health outcomes.
